New 'Living Drug' trial seeks to reboot immune system to fight childhood leukemia
NCT ID NCT04318678
Summary
This study is testing a new type of treatment called CD123-CAR T-cell therapy for children and young adults (up to age 21) whose blood cancers have come back or haven't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back after a short course of chemotherapy. The main goal of this early-phase trial is to find the highest dose of these modified cells that is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.